Aims
To examine incidence of complications associated with outpatient total hip arthroplasty (THA), and to see if medical comorbidities are associated with complications or extended length of stay.

Patients and Methods
From June 2013 to December 2016, 1279 patients underwent 1472 outpatient THAs at our free-standing ambulatory surgery centre. Records were reviewed to determine frequency of pre-operative medical comorbidities and post-operative need for overnight stay and complications which arose.

Results
In 87 procedures, the patient stayed overnight for 23-hour observation, with 39 for convenience reasons and 48 (3.3%) for medical observation, most frequently urinary retention (13), obstructive sleep apnoea (nine), emesis (four), hypoxia (four), and pain management (six). Five patients (0.3%) experienced major complications within 48 hours, including three transferred to an acute facility; there was one death. Overall complication rate requiring unplanned care was 2.2% (32/1472). One or more major comorbidities were present in 647 patients (44%), including previous coronary artery disease (CAD; 50), valvular disease (nine), arrhythmia (219), thromboembolism history (28), obstructive sleep apnoea (171), chronic obstructive pulmonary disease (COPD; 124), asthma (118), frequent urination or benign prostatic hypertrophy (BPH; 217), or mild chronic renal insufficiency (11).

Conclusion
The presence of these comorbidities was not associated with medical or surgical complications. However, presence of one or more major comorbidity was associated with an increased risk of overnight observation. Specific comorbidities associated with increased risk were CAD, COPD, and frequent urination/BPH. Outpatient THA is safe for a large proportion of patients without the need for a standardised risk assessment score. Risk of complications is not associated with presence of medical comorbidities.

Cite this article: Bone Joint J 2018;100-B(1 Supple A):31–5.

Recently, there has been increasing interest in performing total hip arthroplasty (THA) as an outpatient or day-case procedure. This concept has already been safely applied to unicondylar knee arthroplasty. To perform a same day arthroplasty safely, there are many factors that have to be addressed. One factor is the fear and anxiety associated with a new experience of surgery and the concern about management of the surgical pain. A programme for safe outpatient THA must also mitigate against the risk associated with the patients’ comorbidities and reduce the risk of medical complications. Surgeons and care givers associated with outpatient THA must manage the side effects of treatment, including the use of narcotics and anaesthesia, minimising blood loss, and reducing surgical trauma. The purpose of this study is to report the incidence of medical and surgical complications associated with outpatient THA, if patient medical comorbidities are associated with these complications or extended length of stay and to question the need for a complex pre-operative score to determine suitability for outpatient THA.

Patients and Methods
Between June 2013 and December 2016, we performed 1472 outpatient hip arthroplasty procedures in 1279 patients at a free-standing ambulatory surgery centre. All patients signed
A multimodal peri-operative pain management protocol is used, with patients being given a mixture of medications with synergistic actions to reduce the need for narcotic medications post-operatively (Tables II and III). The anaesthetic technique consists of a short-acting spinal neuroaxial block with general anaesthesia. Hypotensive anaesthesia with a mean arterial pressure goal of 60 mm Hg is combined with peri-operative administration of oral tranexamic acid (TXA), with 1 g TXA given two hours prior to incision and a second 1 g dose given three hours after the initial dose. As noted, 90% of cases were performed through the direct anterior approach with the use of a standard operating table.

### Table I. Relative contraindications for outpatient total hip arthroplasty (THA)

| Contraindication                          |
|-------------------------------------------|
| Congestive heart failure                  |
| Valvular disease                          |
| Severe chronic obstructive pulmonary disease |
| Home oxygen use                           |
| Untreated sleep apnoea with body mass index > 40 kg/m² |
| Severe renal disease                      |
| Cerebrovascular accident                  |
| Solid organ transplant                    |

One or more significant medical comorbidities were present in 647 patients (44%). This includes previous coronary artery disease (CAD) in 50 patients, valvular heart
disease in nine, arrhythmia in 219, history of venous thrombotic disease in 28 patients, obstructive sleep apnoea in 171 patients, chronic obstructive pulmonary disease (COPD) in 124 patients, asthma in 118, frequent urination or benign prostatic hypertrophy (BPH) in 217, or mild chronic renal insufficiency in 11 patients. Each of these patients was considered to have been fully optimised pre-operatively and their comorbidities were not associated with medical or surgical complications. With only 11 procedures (0.7%) experiencing a medical complication and a large variety of medical comorbidities being present in our cohort, we could not identify any clear association between these and the patients’ outcome. However, the presence of one or more major comorbidity was associated with a significantly increased risk of needing to stay overnight for observation (Table IV). Specific comorbidities associated with increased risk of requiring an overnight stay were history of CAD, COPD, and frequent urination or BPH. Additionally, the specific medical comorbidities of COPD and frequent urination/BPH were associated with increased risk of need for overnight observation for a related reason, obstructive sleep apnoea and urinary issues, respectively.
Discussion
The current study demonstrates that in medically optimised patients, despite a large proportion of associated medical comorbidities, outpatient THA is associated with a low rate of medical and surgical complications. However, existing medical comorbidities are associated with the need for extended observation and overnight stay. Our data would refute the need or validity of a standardised scoring system for determining the suitability of a patient for outpatient arthroplasty as pre-existing comorbidities were not associated with risk of complication in optimised patients.

We defined significant medical comorbidities as described above and considered CHF, or valvular disease; severe COPD or home use of supplemental oxygen; untreated obstructive sleep apnoea with a BMI > 40 kg/m²; haemodialysis or severely elevated serum creatinine; haemoglobin < 130 g/L; cerebrovascular accident or history of delirium or dementia; and solid organ transplant as relative contraindications for outpatient arthroplasty. These contraindications are similar to those described by Courtney et al, who described an increased risk of medical complications in patients with COPD, CHF, CAD and cirrhosis. The current study, and similarly the series from Courtney et al did not use BMI as an absolute contraindication. Additionally, the ASA Physical Status Classification System was not used in either study. Despite these relative contraindications, patients in 44% of procedures had one or more major medical comorbidities, the presence of which was not associated with medical or surgical complications. These comorbidities were directly related to the need for overnight observation and should be taken in to consideration in centres where overnight stay is not available.

Our rate of overnight stay was 6% with roughly half of these patients staying for reasons of convenience and half requiring additional observation for medical reasons. This is lower than the rate reported by Goyal et al where 24% of 112 cases required overnight stay in the randomised trial. There was a 2.2% incidence of medical or surgical complications in our series. This low rate of unplanned medical care or complications compares favourably with the rates presented in the literature for both inpatient and outpatient THA.

The current study demonstrates that outpatient THA is safe, while Aynardi et al have demonstrated that same-day surgery can provide significant cost savings compared with inpatient care. They compared two groups of THA performed by the same surgeon. The outpatient cohort had a nearly $7000 cost savings per patient over inpatient care.

Outpatient THA is safe for many patients and the risk of complications is not associated with the presence of medical comorbidities. The presence of comorbidities is, however, associated with an increased need for overnight medical observation. The paradigm change of patient education, medical optimisation, and a multimodal programme to limit blood loss and reduce the need for narcotics, results in an ability to perform safely outpatient THA in a large proportion of patients without the need for a standardised risk assessment score.

Take home message:
- Our contraindications for outpatient THA are these ongoing comorbidities that cannot be optimised: congestive heart failure or valvular disease; severe chronic obstructive pulmonary disease or home use of oxygen; untreated obstructive sleep apnoea with a BMI > 40 kg/m²; severe renal disease; anaemia with haemoglobin < 13.0 g/L; cerebrovascular accident or history of delirium or dementia; solid organ transplant.
- Of 1443 procedures in 1279 patients, 48 (3.3%) required a 23-hour overnight stay for medical observation, five patients (0.3%) experienced a major medical complication within 48 hours including three transferred to an acute facility; six additional patients had medical complications within 90 days and one patient died; 21 patients had surgical complications that required further treatment within 90 days for an overall rate of 2.2% (32/1443) medical and surgical complications requiring unplanned care.
- One or more major comorbidities were present in 647 patients (44%). The presence of these comorbidities was not associated with medical or surgical complications. However, presence of one or more major comorbidity was associated with increased risk for overnight medical observation, and specific comorbidities associated with increased risk were coronary artery disease, chronic obstructive pulmonary disease, and frequent urination and/or benign prostatic hypertrophy.

Table IV. Risk of overnight stay for medical reason by major comorbidity

| Major comorbidity                          | Pre-operative finding, n, (%) | Overnight stay for medical reason | Overnight for medical reason with versus without comorbidity (%) | Relative risk | 95% CI | p-value | Odds ratio | 95% CI | p-value |
|-------------------------------------------|------------------------------|----------------------------------|---------------------------------------------------------------|--------------|-------|--------|-----------|-------|--------|
| Coronary artery disease                   | 50 (3.4)                    | 5                                | 10.0 vs 3.2                                                   | 3.09         | 1.3 to 7.4 | 0.012   | 3.32      | 1.3 to 8.8 | 0.015  |
| Valvular disease                          | 9 (0.6)                     | 1                                | 11.1 vs 3.4                                                   | 3.25         | 0.5 to 21.0 | 0.216   | 3.53      | 0.4 to 28.0 | 0.238  |
| Arrhythmia                                | 219 (14.8)                  | 12                               | 5.5 vs 3.1                                                   | 1.76         | 0.9 to 3.3 | 0.079   | 1.80      | 0.9 to 3.5 | 0.081  |
| Venous thromboembolism                    | 28 (1.9)                    | 0                                | 0.0 vs 3.5                                                   | 0.48         | 0.03 to 7.7 | 0.606   | 0.47      | 0.02 to 7.9 | 0.603  |
| Obstructive sleep apnoea                  | 171 (11.6)                  | 7                                | 4.1 vs 3.4                                                   | 1.21         | 0.6 to 2.6 | 0.632   | 1.22      | 0.5 to 2.8 | 0.633  |
| Chronic obstructive pulmonary disease     | 124 (8.4)                   | 10                               | 8.1 vs 3.0                                                   | 2.65         | 1.4 to 5.2 | 0.004   | 2.80      | 1.4 to 5.7 | 0.005  |
| Asthma                                    | 118 (8.0)                   | 9                                | 7.6 vs 3.1                                                   | 2.46         | 1.2 to 4.9 | 0.011   | 2.58      | 1.2 to 5.4 | 0.013  |
| Urinary frequency                         | 217 (14.7)                  | 15                               | 6.9 vs 2.9                                                   | 2.41         | 1.3 to 4.3 | 0.003   | 2.51      | 1.4 to 4.7 | 0.004  |
| Kidney disease                            | 11 (0.8)                    | 1                                | 9.1 vs 3.4                                                   | 2.66         | 0.4 to 17.6 | 0.311   | 2.82      | 0.4 to 22.5 | 0.327  |
| Any major comorbidity                     | 647 (44.0)                  | 33                               | 5.1 vs 2.2                                                   | 2.34         | 1.3 to 4.1 | 0.003   | 2.41      | 1.3 to 4.3 | 0.003  |

CI, confidence interval
- With appropriate optimisation of medical comorbidities, THA may be safely undertaken at an ambulatory surgery centre. However, the likelihood of the need for an overnight stay is related to the presence of pre-operative comorbidity but these comorbidities are not related to the risk of post-operative complications.

**Supplementary material**

A figure showing the frequency of major medical comorbidities in the study group of patients who underwent outpatient total hip arthroplasty can be found alongside the online version of this article at www.bjj.boneandjoint.org.uk

**Author contributions**

K. R. Berend: Collected primary data, Wrote the manuscript.
A. V. Lombardi Jr: Collected primary data, Critically appraised the manuscript.
M. E. Berend: Collected primary data, Critically appraised the manuscript.
J. B. Adams: Collected primary data, Analysed the data, Critically appraised the manuscript.
M. J. Morris: Collected primary data, Critically appraised the manuscript.
K. R. Berend and M. J. Morris report grants and personal fees from Zimmer Biomet, grants from Pacira Pharmaceuticals, grants from OrthoSensor and grants from SPR Therapeutics, outside the submitted work.
A.V. Lombardi Jr reports grants and personal fees from Zimmer Biomet, grants and personal fees from Pacira Pharmaceuticals, and grants and personal fees from OrthoSensor, grants and other from SPR Therapeutics and personal fees from Innomed, outside the submitted work.
M. E. Berend reports grants and personal fees from Zimmer Biomet, grants from Johnson and Johnson and grants from Stryker, outside the submitted work.
J. B. Adams reports grants from Zimmer Biomet, grants from Pacira Pharmaceuticals, grants from OrthoSensor and grants from SPR Therapeutics, outside the submitted work.

The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article. In addition, benefits have been or will be directed to a research fund, foundation, educational institution, or other non-profit organisation with which one or more of the authors are associated.

**References**

1. Pollock M, Somerville L, Firth A, Lanting B. Outpatient total hip arthroplasty, total knee arthroplasty, and unicompartmental knee arthroplasty: a systematic review of the literature. *JBJS Rev* 2016;4:0187/4474–201612000.
2. Bradley B, Middleton S, Davis N, et al. Discharge on the day of surgery following unicompartmental knee arthroplasty within the United Kingdom NHS. *Bone Joint J* 2017;99-B:789–792.
3. Mason JB. The new demands by patients in the modern era of total joint arthroplasty: a point of view. *Clin Orthop Relat Res* 2008;468:146–152.
4. Berend KR, Lombardi AV Jr, Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin. *Am J Orthop (Belle Mead NJ)* 2008;35:24–29.
5. Lee OJ, Chang WY, Wong YC. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. *J Arthroplasty* 2017;32:139–142.
6. Moskal JT, Capps SG. Meta-analysis of intravenous tranexamic acid in primary total hip arthroplasty. *Orthopedics* 2016;39:883–892.
7. Mirza AJ, Lombardi AV Jr, Morris MJ, Berend KR. A mini-anterior approach to the hip for total joint replacement: optimising results: improving hip joint replacement outcomes. *Bone Joint J* 2014;96-B(Supple A):32–35.
8. Courtney PM, Rozell JC, Melnic CM, Lee GC. Who should not undergo short stay hip and knee arthroplasty? Risk factors associated with major medical complications following primary total joint arthroplasty. *J Arthroplasty* 2015;30(suppl):1–4.
9. Saklad M. Grading of patients for surgical procedures. *Anesthesiology* 1941;2:281–284.
10. Goyal N, Chen AF, Padgett SE, et al. Otto Aufranc Award: A multicenter, randomized study of outpatient versus inpatient total hip arthroplasty. *Clin Orthop Relat Res* 2017;475:364–372.
11. Hartog YM, Mathijssen NM, Vehmeijer SB. Total hip arthroplasty in an outpatient setting in 27 selected patients. *Acta Orthop* 2015;86:667–670.
12. Aynardi M, Post Z, Ong A, Orzco F, Sukin DC. Outpatient surgery as a means of cost reduction in total hip arthroplasty: a case-control study. *HSS J* 2014;10:252–255.